Biogen Bets Big To Bag Sage Depression And Tremor Drugs
Paying $1.53bn Upfront For Zuranolone And SAGE-324
Executive Summary
Rather than hitting the acquisition trail, Biogen has taken the licensing route to expand its psychiatric and neurological disorders pipeline.
You may also be interested in...
Zuranolone Launch Requires Sage To Shift The Way Doctors Treat Depression
CEO Barry Greene and team spoke with Scrip about Sage and Biogen’s focus on short-term, episodic dosing, and said doctors and payers – pending zuranolone’s approval – are responding to the sales pitch.
Sage/Biogen Delay Zuranolone Filing, Commercial Path Remains Unclear
The companies will seek approval for zuranolone in MDD second-half 2022 and in PPD in first-half 2023, but that also means launch will probably happen second-half 2023.
Biogen Seeking A Path Forward After Phase III Tofersen Study Fails In ALS
The drug showed favorable but not significant trends across secondary endpoints, and greater efficacy in slower-progressing patients and those treated earlier in the disease, in a small subpopulation.